

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form 4

SYNAPTIC PHARMACEUTICAL CORP

Form 4

December 17, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

FORM 4

Washington, D.C. 20549

OMB APPROVAL

✓ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may

continue. See Instruction 1(b).

STATEMENT OF
CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours
per response 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol		6. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
BVF Partners L.P.			Synaptic Pharmaceutical Corp. ("SNAP")		<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last)	(First)	(Middle)	3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)	4. Statement for Month/Day/Year		
227 West Monroe Street, Suite 4800				December 13, 2002		
(Street)						
Chicago,	Illinois	60606	5. If Amendment, Date of Original (Month/Year)		7. Individual or Joint/Group Filing (Check Applicable Line)	
(City)	(State)	(Zip)			<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/13/02		S	378,000 D	\$6.30	(1)	(1)(2)
Common Stock	12/13/02		S	251,000 D	\$6.30	(1)	(1)(3)
Common Stock	12/13/02		S	578,000 D	\$6.30	(1)	(1)(4)
					504,233		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

*If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Table II Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

[illegible]

7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Securities: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--	---	---	---	---

Title	Amount or Number of Shares

(1)

(2)

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form 4

Shares beneficially owned by BVF, L.P.

(3)

Shares beneficially owned by BVF2, L.P.

(4)

Shares beneficially owned by Investments.

BVF Partners L.P.

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

December 17, 2002

** Signature of Reporting Person

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Control Number.

FORM 4 (Continued)

1. Biotechnology Value Fund, L.P.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

December 17, 2002

**Signature of Reporting Person
Authorized Signatory

Date

2. Biotechnology Value Fund II, L.P.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

December 17, 2002

**Signature of Reporting Person
Authorized Signatory

Date

3. BVF Investments, L.L.C.
227 West Monroe Street, Suite 4800
Chicago, Illinois 60606

BVF INVESTMENTS, L.L.C.

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

December 17, 2002

**Signature of Reporting Person
Authorized Signatory

Date

4. BVF Inc.
One Sansome Street, 31st Floor

BVF INC.

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form 4

San Francisco, California 94104	By: /s/ MARK N. LAMPERT	December 17, 2002
	<hr/>	<hr/>
	**Signature of Reporting Person Authorized Signatory	Date

5. Mark N. Lampert One Sansome Street, 31st Floor San Francisco, California 94104	By: /s/ MARK N. LAMPERT	December 17, 2002
	<hr/>	<hr/>
	**Signature of Reporting Person Authorized Signatory	Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Control Number.

Page 3 of 3
SEC 1474 (03-99)
